Valls-i-Soler A, Fernández-Ruanova B, López-Heredia y Goya J, Román Etxebarría L, Rodriguez-Soriano J, Carretero V
Neonatal Intensive Care Unit, Department of Pediatrics, Hospital de Cruces, Basque University School of Medicine, Bilbao, Bizkaia, Spain.
Pediatrics. 1998 Apr;101(4):E4. doi: 10.1542/peds.101.4.e4.
To determine if 1-minute instillation of Curosurf via a dual-lumen endotracheal tube without interruption of mechanical ventilation could decrease the incidence of hypoxia (drop in oxygen saturation [SaO2] to <80%, or of transcutaneous partial pressure of oxygen [PtcO2] to <50 mm Hg [6.6 kPa]) and bradycardia (heart rate below 80 beats/minute) at dosing, without affecting the efficacy of the standard bolus delivery.
Prospective, multicenter, randomized, nonblinded clinical trial.
Neonatal intensive care units of the Spanish Surfactant Collaborative Group.
One hundred ninety-eight infants (birth weight 600-2000 g) with respiratory distress syndrome needing mechanical ventilation with a fraction of inspired oxygen [FIO2] 0.40 were randomized before 24 hours to receive 200 mg/kg of Curosurf, either by bolus instillation (n = 99) or by a simplified dosing technique (n = 99), giving the full dose in 1 minute via a dual-lumen endotracheal tube without positioning, interruption of mechanical ventilation, or bagging. Two additional doses (100 mg/kg) were given within 12 and 24 hours of first dose, by the same method, if the infant still needed mechanical ventilation and had a FIO2 0.30. The effects of both procedures on the incidence of acute adverse events at dosing, gas exchange, ventilator requirements, and outcome at 28 days were compared.
Fewer episodes of hypoxia (18 vs 40% of doses), and a smaller decrease in heart rate and SaO2 were observed in the dual-lumen group. Efficacy of surfactant, based on improvement of oxygenation, ventilator requirements, and number of doses required, was similar in both groups. Infants in the dual-lumen group had a lower total time exposure to supplemental oxygen (195+/-199 vs 266+/-221 hours). No differences in the incidence of air leaks, intraventricular hemorrhage, patent ductus arteriosus, bronchopulmonary dysplasia, or survival were observed.
A simplified 1-minute Curosurf dosing procedure via a dual-lumen endotracheal tube without fractional doses, ventilator disconnection, changes in the infant's position, or manual bagging was found to reduce the number of dosing-related adverse transient episodes of hypoxia. Although the simplified method appeared to be as effective as bolus delivery, this should be confirmed in a larger trial.
确定通过双腔气管插管在不中断机械通气的情况下1分钟内注入珂立苏,是否能降低给药时低氧血症(氧饱和度[SaO2]降至<80%,或经皮氧分压[PtcO2]降至<50 mmHg[6.6 kPa])和心动过缓(心率低于80次/分钟)的发生率,且不影响标准推注给药的疗效。
前瞻性、多中心、随机、非盲临床试验。
西班牙表面活性剂协作组的新生儿重症监护病房。
198例患有呼吸窘迫综合征、需要机械通气且吸入氧分数[FIO2]为0.40的婴儿(出生体重600 - 2000 g),在24小时前随机分组,分别接受200 mg/kg的珂立苏,一组采用推注给药(n = 99),另一组采用简化给药技术(n = 99),通过双腔气管插管在1分钟内给予全量,无需调整体位、中断机械通气或使用复苏气囊。如果婴儿仍需要机械通气且FIO2为0.30,则在首剂后的12小时和24小时内,通过相同方法再给予两剂(100 mg/kg)。比较两种给药方法在给药时急性不良事件的发生率、气体交换、呼吸机需求以及28天时的结局。
双腔组出现低氧血症发作次数较少(分别为剂量的18%和40%),心率和SaO2下降幅度较小。基于氧合改善、呼吸机需求和所需剂量数量,两组表面活性剂的疗效相似。双腔组婴儿接受补充氧气的总时长较短(195±199小时 vs 266±221小时)。在气胸、脑室内出血、动脉导管未闭、支气管肺发育不良或生存率方面未观察到差异。
通过双腔气管插管采用简化的1分钟珂立苏给药程序,无需分次给药、断开呼吸机、改变婴儿体位或手动使用复苏气囊,可减少给药相关的短暂性低氧血症不良事件数量。尽管简化方法似乎与推注给药同样有效,但这一点应在更大规模的试验中得到证实。